Visceral leishmaniasis masquerading as drug-induced pancytopenia in myasthenia gravis

  • Nath Uttam Kumar
    Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishieksh, India.
  • Bhattacharyya Debmalya
    Department of Haematology, Saroj Gupta Cancer Center & Research Institute, Thakurpukur, Kolkata, India.
  • Chattopadhya Debranjani
    Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishieksh, India.
  • Dhingra Gaurav
    Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishieksh, India.
  • Azad Shweta
    Department of Pathology, All India Institute of Medical Sciences, Rishikesh, India.
  • Mohanty Aroop
    Department of Microbiology, All India Institute of Medical Sciences, Gorakhpur, India.

この論文をさがす

抄録

<p>Visceral leishmaniasis (VL), also known as kala-azar (black fever in Hindi), is a disease primarily caused by Leishmania donovani. The most important clinical manifestation of visceral leishmaniasis is fever. Nonspecific laboratory findings of visceral leishmaniasis include anemia, neutropenia, eosinopenia, and thrombocytopenia. Definitive diagnosis of visceral leishmaniasis requires the demonstration of either parasite by smear or tissue by culture (usually bone marrow or spleen). Myasthenia gravis is an autoimmune disease caused by antibodies to acetylcholine receptors in the post-junctional membrane of the neuromuscular junction. It typically presents with fatigable muscle weakness without any sensory or brain involvement. It is usually treated with corticosteroids and immunosuppressants like azathioprine. Here we encountered a confirmed case of myasthenia gravis on azathioprine with pancytopenia. While working up to evaluate pancytopenia, bone marrow examination revealed presence of Donovan bodies and the patient showed good response to liposomal amphotericin-B. In retrospect, a case of myasthenia gravis, who presented with pancytopenia presumably drug-induced, was found to have visceral leishmaniasis. </p>

収録刊行物

  • Drug Discoveries & Therapeutics

    Drug Discoveries & Therapeutics 15 (1), 48-50, 2021-02-28

    特定非営利活動法人 バイオ&ソーシャル・サイエンス推進国際研究交流会

参考文献 (5)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ